IMUX
IMUX clinical trials: IMMUNIC, INC.
Every trial on ClinicalTrials.gov where IMMUNIC, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 7
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IMUX on the catalyst calendar · IMUX registry changes
- Primary completion Nov 2026Sponsor estimatePhase 3NCT05201638Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisImmunic AG · Multiple Sclerosis, Relapsing-RemittingActive, not recruitingIMUXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 3NCT05134441Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisImmunic AG · Multiple SclerosisActive, not recruitingIMUXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 12, 2021ActualPhase 2/Phase 3NCT04379271A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy...Immunic AG · COVID-19CompletedIMUXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 7, 2025Sponsor estimatePhase 2NCT05054140Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple SclerosisImmunic AG · Multiple SclerosisUnknown statusIMUXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 24, 2020ActualPhase 2NCT03846219MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)Immunic AG · Relapsing-Remitting Multiple Sclerosis (RRMS)Active, not recruitingIMUXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 16, 2022ActualPhase 2NCT03341962Phase 2 Dose-finding IMU-838 for Ulcerative ColitisImmunic AG · Ulcerative ColitisTerminatedIMUXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2023ActualPhase 1NCT05124795IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate CancerImmunic AG · Metastatic Castration Resistant Prostate CancerTerminatedIMUXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 20, 2022ActualPhase 2NCT04516915IMU-838 and Oseltamivir in the Treatment of COVID-19University Hospitals Coventry and Warwickshire NHS Trust · Covid 19CompletedIMUXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner